{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:53Z","timestamp":1790902493337,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:36:58Z","timestamp":1774042618000},"page":"100121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does effective therapy of psoriasis prevent the development of psoriatic arthritis?"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-7924","authenticated-orcid":false,"given":"Kerem","family":"Abacar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Watad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0002","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/annrheumdis-2016-209846","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis","volume":"76","author":"van Steenbergen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2026.01.005_bib66","doi-asserted-by":"crossref","unstructured":"Abacar K, Tabuchi Y, Matteo AD, Duquenne L, Rowbotham E, Nam J, et al. Quantitative MRI tenosynovitis volume explains the association between tendon involvement and future development of clinical arthritis in anti-cyclic citrullinated peptide-positive at-risk individuals. Ann Rheum Dis. 2026 Mar 10. Epub ahead of print. https:\/\/doi.org\/10.1016\/j.ard.2025.10.020","DOI":"10.1016\/j.ard.2025.10.020"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ero.2026.01.005_bib0004","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3899\/jrheum.110505","article-title":"Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis","volume":"38","author":"Tinazzi","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/rheumatology\/kel214","article-title":"The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis\u2013a high-resolution MRI and histological study","volume":"46","author":"Tan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","article-title":"Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis","volume":"75","author":"Simon","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0008","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.41239","article-title":"Association of structural entheseal lesions with an increased risk of progression from psoriasis to psoriatic arthritis","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2026.01.005_bib0009","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ero.2026.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.013","article-title":"Time to transition from psoriasis to psoriatic arthritis: a population-based study","volume":"52","author":"Karmacharya","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ero.2026.01.005_bib0011","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0012","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/acr2.11537","article-title":"Guselkumab, a selective interleukin-23 p19 Subunit Inhibitor, resolves dactylitis in patients with active psoriatic arthritis: pooled results through week 52 from two phase 3 studies","volume":"5","author":"McGonagle","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2026.01.005_bib0014","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ero.2026.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0016","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jid.2015.11.026","article-title":"Genome-wide pathway analysis identifies genetic pathways associated with psoriasis","volume":"136","author":"Aterido","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.ero.2026.01.005_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41590-025-02351-z","article-title":"Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints","volume":"27","author":"Raimondo","year":"2026","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.ero.2026.01.005_bib0019","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+ CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ero.2026.01.005_bib0020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6965","key":"10.1016\/j.ero.2026.01.005_bib0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature02119","article-title":"Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice","volume":"426","author":"Sakaguchi","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ero.2026.01.005_bib0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1084\/jem.20041758","article-title":"A role for fungal beta-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice","volume":"201","author":"Yoshitomi","year":"2005","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.ero.2026.01.005_bib0023","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.34423","article-title":"\u03b2-glucan triggers spondylarthritis and Crohn\u2019s disease-like ileitis in SKG mice","volume":"64","author":"Ruutu","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13075-021-02693-7","article-title":"A role for neutrophils in early enthesitis in spondyloarthritis","volume":"24","author":"Stavre","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/03009740802448833","article-title":"Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis","volume":"38","author":"Marzo-Ortega","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.ero.2026.01.005_bib0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3899\/jrheum.2024-0593","article-title":"GRAPPA 2023 Debate: is psoriatic disease really a primary enthesitis that drives joint synovitis? The enthesitis hypothesis 25 years on","volume":"51","author":"McGonagle","year":"2024","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2026.01.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255492","article-title":"The risk of psoriasis in patients with uveitis: a nationwide population-based cohort study","volume":"16","author":"Chen","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ero.2026.01.005_bib0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","article-title":"Risk of uveitis among people with psoriasis: a nationwide cohort study","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ero.2026.01.005_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100067","article-title":"Characteristics and sources of tissue-resident memory T cells in psoriasis relapse","volume":"4","author":"Dong","year":"2023","journal-title":"Curr Res Immunol"},{"key":"10.1016\/j.ero.2026.01.005_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652191","article-title":"Resident memory T cells in autoimmune skin diseases","volume":"12","author":"Ryan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ero.2026.01.005_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1111521","article-title":"Tissue-resident memory T cells in renal autoimmune diseases","volume":"14","author":"Ginsberg","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ero.2026.01.005_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912393","article-title":"An overview of tissue-resident memory T cells in the intestine: from physiological functions to pathological mechanisms","volume":"13","author":"Lyu","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ero.2026.01.005_bib0033","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.autrev.2017.07.011","article-title":"Autoimmune aspects of psoriasis: heritability and autoantigens","volume":"16","author":"Prinz","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.ero.2026.01.005_bib0034","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.ero.2026.01.005_bib0035","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.ero.2026.01.005_bib0036","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-025-00964-6","article-title":"Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless Phase 3, open-label extension trial results","volume":"26","author":"Papp","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0037","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"15","key":"10.1016\/j.ero.2026.01.005_bib0038","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178213","article-title":"Psoriatic arthritis subtypes are phenocopied in humanized mice","volume":"9","author":"Ritchlin","year":"2024","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ero.2026.01.005_bib0039","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2020-217309","article-title":"Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression","volume":"79","author":"Watad","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ero.2026.01.005_bib0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41584-024-01107-7","article-title":"Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis","volume":"20","author":"Chang","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrrheum.2016.200","article-title":"Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis","volume":"13","author":"Catrina","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"7760","key":"10.1016\/j.ero.2026.01.005_bib0042","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ero.2026.01.005_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708186","article-title":"Macrophages: the good, the bad, and the gluttony","volume":"12","author":"Ross","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ero.2026.01.005_bib0044","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10230","key":"10.1016\/j.ero.2026.01.005_bib0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ero.2026.01.005_bib0046","doi-asserted-by":"crossref","unstructured":"van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, et al. EULAR\/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. Arthritis Rheumatol. 2025 May 8. Epub ahead of print. https:\/\/doi.org\/10.1002\/art.43218","DOI":"10.1002\/art.43218"},{"issue":"2","key":"10.1016\/j.ero.2026.01.005_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.ero.2026.01.005_bib0048","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","article-title":"Obesity and the risk of psoriatic arthritis: a population-based study","volume":"71","author":"Love","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0049","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.ero.2026.01.005_bib0050","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0051","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjd.18227","article-title":"Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis","volume":"182","author":"Green","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0052","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.ero.2026.01.005_bib0053","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2018-213025","article-title":"Ultrasonography in psoriatic arthritis: which sites should we scan?","volume":"77","author":"Zabotti","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0054","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2014-205839","article-title":"High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis","volume":"74","author":"Tan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2026.01.005_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0056","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.40778","article-title":"Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0057","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0058","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0059","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2026.01.005_bib0060","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.ero.2026.01.005_bib0061","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","volume":"84","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0062","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/rheumatology\/keae399","article-title":"Subclinical psoriatic arthritis and disease interception-where are we in 2024?","volume":"64","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ero.2026.01.005_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.ero.2026.01.005_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ero.2026.01.005_bib0065","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:18:55Z","timestamp":1790900335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050708126000054"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.01.005","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does effective therapy of psoriasis prevent the development of psoriatic arthritis?","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100121"}}